CDC Panel Considers Delaying Hepatitis B Vaccine for Newborns
The CDC's Advisory Committee on Immunization Practices is set to vote on delaying the hepatitis B vaccine for newborns, a move that has raised concerns among health experts about potential increases in infection rates.
The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) is scheduled to vote on Thursday regarding a proposal to delay the administration of the hepatitis B vaccine from birth to age 4. This recommendation comes from the newly appointed panel by Health Secretary Robert F. Kennedy Jr., who has expressed skepticism about certain vaccine practices.
For over three decades, the CDC has recommended that infants receive the first dose of the hepatitis B vaccine at birth, a strategy that has led to a 99% reduction in infection rates among individuals aged 19 and younger between 1990 and 2022. Health experts warn that postponing the vaccine could result in increased cases of hepatitis B among children.
Dr. Eric Ball, a pediatrician in Orange County, California, emphasized the importance of the current vaccination schedule: "We recommend a universal approach to prevent those cases where a test might be incorrect or a mother might have unknowingly contracted hepatitis. It's really the best way to keep our entire population healthy."
The ACIP meeting, set for September 18-19 in Atlanta, Georgia, will also address recommendations for other vaccines, including the combined measles, mumps, rubella, and varicella vaccine, as well as COVID-19 vaccines. Changes to these schedules could affect vaccine accessibility, as ACIP's recommendations often influence insurance coverage and federal program funding.
Typically, ACIP conducts thorough analyses before altering vaccine guidelines. However, as of late August, such a review had not commenced for the hepatitis B vaccine, according to former CDC officials. Dr. Demetre Daskalakis, former director for the National Center for Immunization and Respiratory Diseases, noted, "This is an atypical situation. There's been no work group to discuss it."
In response to concerns, Health and Human Services spokesman Andrew Nixon stated, "ACIP exists to ensure that vaccine policy is guided by the best available evidence and open scientific deliberation. Any updates to recommendations will be made transparently with gold standard science."
The draft agenda for the upcoming ACIP meeting was released to the public only days before the scheduled dates, raising questions about the transparency and timing of the proposed changes.